KalVista Pharmaceuticals
55 Cambridge Parkway
Suite 901E
Cambridge
Massachusetts
02142
United States
Tel: 857-999 0075
Fax: 866-553 3269
Website: http://www.kalvista.com/
Email: info@kalvista.com
180 articles about KalVista Pharmaceuticals
-
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
3/18/2024
KalVista Pharmaceuticals, Inc. announced that it presented multiple analyses of the relationship between the time to attack treatment and the effects delays in treatment have on clinical outcomes of people living with hereditary angioedema at the 2024 HAEi Regional Conference Americas that took place in Panama City, Panama.
-
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
3/12/2024
KalVista Pharmaceuticals, Inc. announced the UK Medicines and Healthcare products Regulatory Agency has awarded the Promising Innovative Medicine designation for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.
-
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update - March 11, 2024
3/11/2024
KalVista Pharmaceuticals, Inc. provided an operational update and released financial results for the third fiscal quarter ended January 31, 2024.
-
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
3/8/2024
KalVista Pharmaceuticals, Inc. today announced the acceptance of multiple abstracts at the 2024 HAEi Regional Conference meeting taking place in Panama City, Panama from March 15-17.
-
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
3/7/2024
KalVista Pharmaceuticals, Inc. announced that Benjamin L. Palleiko, the Company’s current President, CBO and CFO, has been appointed as Chief Executive Officer and a director of the Company, effective immediately.
-
KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
3/6/2024
KalVista Pharmaceuticals, Inc. announced that its management will participate in a fireside chat at the Leerink Partners 2024 Global Biopharma Conference on Tuesday, March 12th, 2024 at 9:20 a.m. ET in Miami, FL.
-
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 04, 2024
3/4/2024
KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted seven newly-hired employees inducement options to purchase an aggregate of 43,000 shares of KalVista common stock on March 1, 2024 as inducements material to each employee entering into employment with KalVista.
-
KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
2/27/2024
KalVista Pharmaceuticals, Inc. announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting that took place in Washington, DC.
-
KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
2/26/2024
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that it presented additional data on its phase 3 KONFIDENT trial for sebetralstat, including a more in-depth analysis of sebetralstat efficacy and safety at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Washington, DC.
-
KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat
2/20/2024
KalVista Pharmaceuticals, Inc. announced the UK Medicines and Healthcare products Regulatory Agency has awarded the Innovation Passport for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.
-
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
2/16/2024
KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting taking place in Washington, DC from February 23-26.
-
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
2/15/2024
KalVista Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 7,016,312 shares of its common stock at a price to the public of $15.25 per share and pre-funded warrants to purchase 3,483,688 shares of common stock in lieu of KalVista common stock to certain investors.
-
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - February 14, 2024
2/14/2024
KalVista Pharmaceuticals, Inc. announced that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of common stock in lieu of KalVista common stock to certain investors in an underwritten public offering.
-
KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema
2/13/2024
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced positive results from the phase 3 KONFIDENT clinical trial demonstrating statistically and clinically significant efficacy of sebetralstat as oral on-demand therapy for hereditary angioedema (HAE).
-
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 2, 2024
2/2/2024
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 42,000 shares of KalVista common stock on February 1, 2024 as inducements material to each employee entering into employment with KalVista.
-
KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology
12/20/2023
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that data from the first report of an oral, potent, and selective FXIIa inhibitor has been published in the peer-reviewed scientific journal, Frontiers in Pharmacology.
-
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
12/7/2023
KalVista Pharmaceuticals, Inc . today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2023.
-
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 05, 2023
12/5/2023
KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 43,000 shares of KalVista common stock on December 1, 2023 as inducements material to each employee entering into employment with KalVista.
-
KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
11/14/2023
KalVista Pharmaceuticals, Inc. announced that it presented real-world data on anxiety associated with the use of injectable on-demand treatments for hereditary angioedema attacks and patient perspectives on why people living with HAE don’t often carry their on-demand treatment outside the home at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology in Anaheim, CA.
-
KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved
11/13/2023
KalVista Pharmaceuticals, Inc. provided clinical trial and regulatory updates for its lead program sebetralstat, in development as a potential oral on-demand therapy for hereditary angioedema.